メインコンテンツに移動

GSK ‘distraction’

Bondholders do not expect the shareholders’ rejection of GlaxoSmithKline CEO Jean-Paul Garnier’s controversial remuneration package to have any meaningful knock-on effects in the credit universe. In fact, some are concerned that heavy coverage of the headline-friendly event is distracting much-needed attention from more salient corporate governance issues.

Nigel Sillis, research analyst at

コンテンツを印刷またはコピーできるのは、有料の購読契約を結んでいるユーザー、または法人購読契約の一員であるユーザーのみです。

これらのオプションやその他の購読特典を利用するには、info@risk.net にお問い合わせいただくか、こちらの購読オプションをご覧ください: http://subscriptions.risk.net/subscribe

現在、このコンテンツをコピーすることはできません。詳しくはinfo@risk.netまでお問い合わせください。

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

ログイン
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here